Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06082960 · ClinicalTrials.gov registry record · Phase 1
Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors
A Phase 1 study of Solid Tumors, sponsored by Gilead Sciences.
- Active
- Registry status
- Phase 1
- Development phase
- 45
- Enrollment target
- 6
- Study locations
NCT06082960: Active Phase 1 study of Solid Tumors, sponsored by Gilead Sciences.
NCT06082960 is a Phase 1 study of Solid Tumors that is active but no longer recruiting, run by Gilead Sciences. The registered enrollment target is 45 participants, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (84% lower). The trial reports 6 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06082960, a Phase 1 study of Solid Tumors, is active but no longer recruiting, sponsored by Gilead Sciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 45 participants
- Enrollment target
- 6
- Study locations
Study Summary
The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors. The primary objectives of this study are to: * Assess the safety and tolerability of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors * Identify the maximum tolerated dose (MTD)/maximum administered dose (MAD) and the recommended dose for expansion (RDE) of GS-9911 as monotherapy and in combination with an anti-PD-1 monoclonal antibody in participants with advanced solid tumors
Conditions Studied
Interventions
- DRUG Zimberelimab
- DRUG GS-9911
Study Locations (6)
Texas
- NEXT Oncology - San Antonio
- South Texas Accelerated Research Therapeutics, LLC - San Antonio
Connecticut
- Smilow Cancer Hospital Phase 1 Unit - New Haven
Tennessee
- SCRI Oncology Partners - Nashville
Victoria
- Peter MacCallum Cancer Centre - Melbourne
Other
- University Health Network, Princess Margaret Cancer Centre - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2023-10-09 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
What the registry record for NCT06082960 still lists
NCT06082960 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 284-participant average among 125 other Solid Tumors trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Solid Tumors appearing as the primary indexed condition, and to 2 interventions - of which Zimberelimab is the first listed.
NCT06082960 lists 6 locations in 5 states (Texas, Connecticut, Tennessee).
Frequently Asked Questions
What is clinical trial NCT06082960 about?
NCT06082960 is a clinical study titled "Study of GS-9911 With or Without Antibody Treatment for Adults With Solid Tumors". The main goal of this first in human (FIH) study is to learn about the safety and dosing of GS-9911 when given alone or in combination with an anti-programmed cell death protein 1 (PD-1) monoclonal antibody in participants with advanced solid tumors. The primary objectives of this study are to: * ...
What is the current status of trial NCT06082960?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2023-10-09. Estimated completion is 2026-11.
What conditions does trial NCT06082960 study?
This clinical trial studies the following conditions: Solid Tumors.
What interventions are being tested in trial NCT06082960?
The interventions under investigation include: Zimberelimab (DRUG), GS-9911 (DRUG).
Who is sponsoring clinical trial NCT06082960?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06082960 being conducted?
This trial has 6 study locations across Connecticut, Tennessee, Texas, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumors
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06082960's enrollment target sits among peer trials
45 86th of 125 higher than 38 of 125 other Solid Tumors trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumors trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of BG-C0902 Alone and in Combination With Other Therapeutic Agents in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of INCB123667 in Subjects With Advanced Solid Tumors
RECRUITING · Phase 1
-
JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
RECRUITING · Phase 1
-
Study of AUBE00 in Patients With Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI